Tirzepatide
A dual GIP/GLP-1 that pairs appetite reduction with improved insulin sensitivity — often chosen for stronger results.
Two signals at once, deeper response.
A once-weekly dual GIP/GLP-1 that combines appetite control with improved insulin sensitivity — often chosen when a stronger response is the goal.
How it works
Tirzepatide acts on two hormones at once — GLP-1 and GIP. That dual signal quiets appetite while also supporting how your body handles glucose, which is why response often deepens past the third month.
Your clinician maps out a titration schedule that prioritizes tolerance, moving up only when you're ready. Slower steps aren't a setback — they're usually why the dose sticks and the side effects don't.
What to expect
- CadenceOnce-weekly self-injection at home.
- DosingStarts at 2.5 mg/week and titrates up to 15 mg as tolerated.
- ResponseStrong appetite reduction, often more pronounced past month 3.
- DeliveryShips with a fine-gauge needle for a quick, comfortable weekly injection.
- Side-effect patternGI symptoms early in titration; a slower step-up typically improves tolerance.
Who it's for
Tirzepatide tends to be the right call when you want a stronger appetite response, when semaglutide has plateaued, or when metabolic health markers are part of the picture. It's not a fit for everyone — a short intake tells us which.
- Adults 18+ with a BMI of 27+ (or 25+ with a weight-related condition).
- Looking for a stronger response than semaglutide typically delivers.
- Comfortable with a once-weekly at-home injection and a patient titration.
- Interested in the metabolic and glucose-handling benefits alongside weight loss.
- —Personal or family history of medullary thyroid carcinoma or MEN 2.
- —History of pancreatitis, severe GI disease, or gastroparesis.
- —Currently pregnant, planning pregnancy, or breastfeeding.
- —Under 18, or with a BMI below the clinical threshold.
Your first 90 days
Tirzepatide response tends to deepen quarter over quarter. The first 90 days are less about hitting a maximum dose and more about arriving at one you tolerate cleanly.
- Days 1–30Onboarding at 2.5 mg
Your first weekly dose is 2.5 mg — a starter dose meant to acclimate your body, not to drive weight loss on its own. Expect a subtle drop in appetite and cravings by week two or three. Mild nausea early is common and usually settles.
- Days 31–60Step up to 5 mg
If tolerance is good, your clinician moves you to 5 mg — the first true therapeutic dose. Portions feel notably smaller and steady weekly change on the scale becomes the norm.
- Days 61–90Toward 7.5 mg
Most patients step to 7.5 mg by the end of month three. You'll have a clear sense of your response, and your clinician will decide whether to hold or continue stepping up in the months ahead.
What the average patient loses
Tirzepatide's dual-agonist mechanism tends to produce a deeper response than single-GLP-1 therapy. The numbers below reflect averages reported in the largest trials — a realistic reference, not a promise. Individual response varies with dose, adherence, food, and movement.
Early response as titration reaches a therapeutic dose.
Momentum deepens noticeably in months four through six.
Typical average at maintenance dose in long-term studies.
Averages are of total body weight loss and are drawn from published trials of tirzepatide (e.g., SURMOUNT program). Individual results vary and are not guaranteed.
Compounded tirzepatide is not FDA-approved. It's prepared by a licensed pharmacy from a valid prescription written by a licensed provider.
Tirzepatide
A dual GIP/GLP-1 that pairs appetite reduction with improved insulin sensitivity — often chosen for stronger results.
